Stockreport

LIXTE Biotechnology Holdings (LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape [Yahoo! Finance]

Lixte Biotechnology Holdings, Inc.  (LIXT) 
NASDAQ:AMEX Investor Relations: lixte.com/investor_information_02.php
PDF "The company is best known for its clinical-stage pharmaceutical pipeline built around LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A')," a recent ar [Read more]